Trial Profile
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Samotolisib (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Apr 2022 Results published in the Clinical Cancer Research
- 04 May 2020 Status changed from active, no longer recruiting to completed.
- 21 Apr 2020 Planned End Date changed from 14 Feb 2020 to 30 Apr 2020.